Pharmacological profiling studies identified synergistic drug combinations with ibrutinib in activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL)13,14 or NF-κB-targeted strategies in mantle cell lymphoma (MCL)15. Here, NFKB1 is linked to diffuse large B-cell lymphoma.